Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.
Fiche publication
Date publication
mars 2018
Journal
Blood
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LIPSKER Dan
Tous les auteurs :
Rowczenio DM, Pathak S, Arostegui JI, Mensa-Vilaro A, Omoyinmi E, Brogan P, Lipsker D, Scambler T, Owen R, Trojer H, Baginska A, Gillmore JD, Wechalekar AD, Lane T, Williams R, Youngstein T, Hawkins PN, Savic S, Lachmann HJ
Lien Pubmed
Résumé
To date, the pathogenic mechanisms underlying Schnitzler syndrome remain obscure, in particular, the interplay between the monoclonal protein and increased interleukin-1β (IL-1β) production, although interest in the contribution of genetic factors has been fueled by detection of somatic mosaicism in 2 patients with the variant-type Schnitzler syndrome. At 2 specialist UK centers, we have identified 21 patients who fulfilled diagnostic criteria for Schnitzler syndrome with urticarial rash, fever, arthralgia, and bone pain; 47% reported weight loss, 40% fatigue, and 21% lymphadenopathy. An immunoglobulin M (IgM) κ paraprotein was detected in 86%; the remainder had IgM λ or IgG κ. Patients underwent searches for germ line and somatic mutations using next-generation sequencing technology. Moreover, we designed a panel consisting of 32 autoinflammatory genes to explore genetic susceptibility factor(s) to Schnitzler syndrome. Genetic analysis revealed neither germ line nor somatic , , , or mutations, apart from 1 patient with a germ line p.V198M substitution. The proinflammatory cytokines and extracellular apoptosis-associated speck-like protein with caspase recruitment domain (ASC) measured in the serum of Schnitzler syndrome patients during active disease were significantly higher than healthy controls. Ninety-five percent of our cohort achieved a complete response to recombinant IL-1 receptor antagonist (anakinra). Our findings do not support a role for somatic mosaicism in disease pathogenesis; although elevated levels of ASC, IL-6, and IL-18 in patients' serum, and the response to anakinra, suggest that Schnitzler syndrome is associated with upregulated inflammasome activation. Despite its rarity, Schnitzler syndrome is an important diagnosis as treatment with IL-1 antagonists dramatically improves quality of life for patients.
Mots clés
Adult, Aged, Amino Acid Substitution, CARD Signaling Adaptor Proteins, genetics, Calcium-Binding Proteins, genetics, Female, Germ-Line Mutation, Humans, Interleukin 1 Receptor Antagonist Protein, administration & dosage, Interleukin-18, blood, Interleukin-6, blood, Male, Middle Aged, NLR Family, Pyrin Domain-Containing 3 Protein, genetics, Nod2 Signaling Adaptor Protein, genetics, Receptors, Tumor Necrosis Factor, Type I, genetics, Schnitzler Syndrome, blood
Référence
Blood. 2018 Mar 1;131(9):974-981